LUYE PHARMA GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.6 HKD | -2.99% |
|
-7.80% | -30.29% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Companyâs main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimerâs disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.478
CNY
Average target price
2.775
CNY
Spread / Average Target
+11.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.29% | 1.29B | |
| +28.72% | 676B | |
| +23.98% | 559B | |
| -8.13% | 356B | |
| +15.78% | 320B | |
| +5.18% | 286B | |
| +2.55% | 213B | |
| -0.12% | 207B | |
| -9.61% | 199B | |
| -8.02% | 142B |
- Stock Market
- Equities
- 2186 Stock
- News Luye Pharma Group Ltd.
- Chinese Regulators Approve Luye's Initiation of Clinical Trials for Parkinson's Disease Treatment
